IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.061
AS - Asia 3.089
NA - Nord America 2.978
SA - Sud America 392
AF - Africa 40
OC - Oceania 5
Totale 13.565
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.116
US - Stati Uniti d'America 2.915
SG - Singapore 1.029
CN - Cina 602
IE - Irlanda 600
IT - Italia 549
HK - Hong Kong 546
VN - Vietnam 391
BR - Brasile 337
DE - Germania 236
KR - Corea 182
GB - Regno Unito 147
IN - India 104
FR - Francia 76
JP - Giappone 71
UA - Ucraina 65
SE - Svezia 48
CA - Canada 39
FI - Finlandia 38
GR - Grecia 33
NL - Olanda 31
TR - Turchia 29
AT - Austria 28
PK - Pakistan 28
PL - Polonia 26
BD - Bangladesh 23
AR - Argentina 21
CZ - Repubblica Ceca 17
MX - Messico 17
BE - Belgio 15
ID - Indonesia 14
IQ - Iraq 12
ES - Italia 11
ZA - Sudafrica 11
EC - Ecuador 10
AZ - Azerbaigian 9
MA - Marocco 7
UZ - Uzbekistan 7
PY - Paraguay 6
SA - Arabia Saudita 6
KE - Kenya 5
VE - Venezuela 5
AU - Australia 4
CO - Colombia 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LT - Lituania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
IL - Israele 3
MK - Macedonia 3
PE - Perù 3
PH - Filippine 3
TH - Thailandia 3
AL - Albania 2
AO - Angola 2
BO - Bolivia 2
CL - Cile 2
CR - Costa Rica 2
EG - Egitto 2
GI - Gibilterra 2
IR - Iran 2
LK - Sri Lanka 2
MY - Malesia 2
SN - Senegal 2
TW - Taiwan 2
UY - Uruguay 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 13.565
Salva come PNG Salva come JPEG
Città #
Moscow 1.834
Dublin 586
Hong Kong 534
San Jose 522
Singapore 514
Santa Clara 404
Chandler 282
Seoul 182
Ashburn 179
Naples 146
Ho Chi Minh City 133
Hefei 109
Jacksonville 108
Dallas 103
Hanoi 94
Beijing 92
New York 86
Los Angeles 75
Munich 69
Bremen 68
Princeton 66
Roxbury 66
Bengaluru 57
The Dalles 53
Caserta 43
Cambridge 37
São Paulo 34
Ann Arbor 33
Medford 29
Da Nang 24
Haiphong 24
Warsaw 24
Milan 22
Wilmington 20
Nuremberg 19
Tokyo 17
Amsterdam 16
Brno 16
Brooklyn 16
Elora 16
Vienna 15
Boardman 14
Council Bluffs 14
Des Moines 14
Falkenstein 14
Napoli 13
Atlanta 12
Brussels 12
Chennai 12
Hải Dương 12
Rome 12
Woodbridge 12
Orem 11
Rio de Janeiro 11
San Francisco 11
Houston 10
Lappeenranta 10
London 10
Turku 10
Baku 9
Belo Horizonte 9
Hillsboro 9
Istanbul 9
Manchester 9
Rawalpindi 9
San Mateo 9
Columbus 8
Ercolano 8
Montreal 8
Ninh Bình 8
Shanghai 8
Aversa 7
Helsinki 7
Jinan 7
Nanjing 7
Tianjin 7
City of London 6
Denver 6
Dong Ket 6
Frankfurt am Main 6
Poplar 6
Pozzuoli 6
Rimini 6
Seattle 6
Stockholm 6
Tashkent 6
Toronto 6
Bahawalpur 5
Battipaglia 5
Biên Hòa 5
Brasília 5
Cape Town 5
Chicago 5
Dhaka 5
Düsseldorf 5
Frosinone 5
Jakarta 5
Johannesburg 5
Madrid 5
Menlo Park 5
Totale 7.250
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 219
AXL is an oncotarget in human colorectal cancer 194
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 192
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 182
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 178
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 177
Immunotherapy for head and neck cancer: Present and future 171
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 170
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 159
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 158
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 158
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 157
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 157
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 156
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 154
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 154
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 150
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 150
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 149
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 149
Clinical management of metastatic colorectal cancer in the era of precision medicine 149
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 148
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 146
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 145
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 144
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 144
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 143
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 142
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 141
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 140
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 139
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 139
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 139
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 138
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 138
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 137
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 134
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 133
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 132
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 131
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 129
Pimasertib hydrochloride 127
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 126
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 125
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 124
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 123
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 123
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 122
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 121
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 120
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 120
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 120
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 119
Prevention of cardiovascular complications in elderly cancer patients 119
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 117
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 116
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 115
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 115
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 115
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 114
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 114
It is finally time for adjuvant therapy in melanoma 113
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 113
Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review 112
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 112
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 112
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 111
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 111
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 111
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 110
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 109
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 107
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 107
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 107
Hypothalamic–pituitary autoimmunity in patients treated with anti-pd-1 and anti-pd-l1 antibodies 106
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 105
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 105
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 103
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 103
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 102
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 101
How we treat locoregional melanoma 97
Novel in vitro cancer models for optimizing anti- EGFR therapies 96
How we treat metastatic colorectal cancer 95
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 94
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 94
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 93
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 92
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 92
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 92
Obesity correlates to the microsatellite instability of endometrial cancer: A retrospective observational study 90
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 88
Totale 12.963
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.478
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 0 0 0 0 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/20252.156 52 53 30 98 295 295 277 221 265 242 182 146
2025/20268.731 382 448 431 353 743 4.753 565 449 378 229 0 0
Totale 13.825